Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart ...
The Manila Times

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial”)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart ...